Achaogen Stock

AKAOQ

US0044491043

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	+278.79%

12/06/20	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/05/20	Achaogen, Inc. Went Out of Business	CI

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Employees

Sector

More about the company

Market Cap	639K 571K 524K 476K 894K 60.51M 917K 6.26M 2.52M 31.94M 2.4M 2.35M 101M	P/E 2017	-3.39x	P/E 2018	-0.29x
Enterprise Value	19.47M 17.39M 15.98M 14.51M 27.25M 1.84B 27.93M 191M 76.71M 973M 73.07M 71.51M 3.08B	EV / Sales 2017	28x	EV / Sales 2018	8.66x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

12/06/20	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/05/20	Achaogen, Inc. Went Out of Business	CI
29/05/20	First Amended Joint Liquidation Plan and Disclosure Statement Approved for Achaogen, Inc.	CI
22/04/20	First Amended Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
21/04/20	Disclosure Statement Approved on Interim Basis for Achaogen, Inc.	CI
30/03/20	Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
09/01/20	Motion for Asset Sale Approved for Achaogen, Inc.	CI
29/12/19	Motion for Asset Sale Filed by Achaogen, Inc.	CI
24/09/19	Final DIP Financing Approved for Achaogen, Inc.	CI
29/08/19	Motion for Exclusivity Period Extension Approved For Achaogen, Inc.	CI
13/08/19	First Motion for Exclusivity Period Extension Filed by Achaogen, Inc.	CI
30/07/19	Achaogen, Inc. Announces Management Changes	CI
23/07/19	Motion for Asset Sale Approved for Achaogen, Inc.	CI

	2017	2018
Net sales	11.18M 9.98M 9.17M 8.33M 15.64M 1.06B 16.03M 109M 44.04M 559M 41.95M 41.05M 1.77B	8.73M 7.8M 7.16M 6.51M 12.22M 827M 12.52M 85.5M 34.39M 436M 32.76M 32.06M 1.38B
Net income	-126M -112M -103M -93.62M -176M -11.9B -180M -1.23B -495M -6.28B -472M -461M -19.91B	-187M -167M -153M -139M -261M -17.67B -268M -1.83B -735M -9.33B -700M -685M -29.56B
Net Debt	-143M -128M -117M -106M -200M -13.53B -205M -1.4B -563M -7.14B -536M -525M -22.63B	18.83M 16.82M 15.45M 14.03M 26.35M 1.78B 27.01M 184M 74.19M 941M 70.67M 69.16M 2.98B

Achaogen Stock

Stocks

AKAOQ

US0044491043

Valuation: Achaogen

Latest news: Achaogen

Financials

Company Profile